Cargando…

Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice

Treatment of von Willebrand disease typically requires multiple infusions of von Willebrand factor (VWF)/factor VIII (FVIII) concentrate. Accumulation of FVIII is a clinical concern due to potential risk for thromboembolism. This study sought to determine whether VWF/FVIII concentrate of high VWF:FV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raquet, Elmar, Stockschlaeder, Marcus, Mueller-Cohrs, Jochen, Zollner, Sabine, Pragst, Ingo, Dickneite, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500654/ https://www.ncbi.nlm.nih.gov/pubmed/25767894 http://dx.doi.org/10.1097/MBC.0000000000000269

Ejemplares similares

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD
por: Flood, Veronica H., et al.
Publicado: (2018)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
por: Comerford, Claire, et al.
Publicado: (2022)

Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels
por: Antoni, Guillemette, et al.
Publicado: (2011)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study
por: Bravo, Maria Isabel, et al.
Publicado: (2022)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
por: Rugeri, Lucia, et al.
Publicado: (2022)

Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance
por: Doherty, Dearbhla, et al.
Publicado: (2022)

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)
por: Auerswald, Guenter, et al.
Publicado: (2020)

Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
por: De Padua, Valeria, et al.
Publicado: (2020)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)
por: Lissitchkov, Toshko J., et al.
Publicado: (2017)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

VWF springs into action
por: Wells, William A.
Publicado: (2006)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

VWF, Platelets and the Antiphospholipid Syndrome
por: Huang, Shengshi, et al.
Publicado: (2021)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
por: Lubich, Christian, et al.
Publicado: (2022)

Genetic variations in sites of affinity between FVIII and LRP1 are not associated with high FVIII levels in venous thromboembolism
por: Bittar, Luis F., et al.
Publicado: (2015)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)
por: Lissitchkov, Toshko, et al.
Publicado: (2020)

DDAVP Might Reduce the Risk of Preeclampsia in Pregnant Women with VWF Deficiency
por: Jahromi, Alireza Hamidian, et al.
Publicado: (2013)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
por: Rodriguez, Martin, et al.
Publicado: (2023)

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2018)

Staphylococcus aureus vWF-binding protein triggers a strong interaction between clumping factor A and host vWF
por: Viljoen, Albertus, et al.
Publicado: (2021)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
por: Swystun, Laura L, et al.
Publicado: (2023)

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain
por: Robador, Jose R, et al.
Publicado: (2021)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin
por: Kovacevic, Katarina D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2h0p029ba74vnq01rljdrv0ao0